BillionToOne is trading 4.04% up at $96.05 following the September 1, 2026 launch of Northstar Origin.
- Northstar Origin is a liquid-biopsy add-on predicting cancer tissue of origin from a single blood draw.
- Northstar Select expanded from 84 to 102 genes, with validation showing 87% top-prediction accuracy and 91% accuracy within the top three predictions.
- The tests are laboratory-developed and not FDA-cleared or approved.